Full Press Release Details
DALLAS, July 14, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Stereotaxis Inc. (Nasdaq:STXS). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/STXS
STXS is trading near its upper Bollinger Band. This suggests that the stock price is high relative to its recent price action.
Stereotaxis Inc. (STXS) designs, manufactures and markets cardiology instrument control systems for use in a hospital's interventional medical suite, or interventional lab, for the treatment of arrhythmias and coronary artery disease by enabling therapeutic solutions and improving catheter-based, or interventional procedures. Its Niobe system allows physicians to navigate catheters, guidewires and other delivery devices through the blood vessels and chambers of the heart to treatment sites to effect treatment. The Company's Odyssey Enterprise Solution allows physicians to utilize a consolidated user interface and single mouse and keyboard control for multiple systems within the interventional lab. The Niobe system is designed for use by interventional electrophysiologists in the treatment of abnormal heart rhythms known as arrhythmias and by interventional cardiologists in the treatment of coronary artery disease.
Message Board Search for STXS: http://www.boardcentral.com/boards/STXS
In the report, the analyst notes:
"STXS said it generated new capital orders of $10.2 million during the quarter, more than doubling new capital orders from the same quarter a year ago. 'Our new capital order momentum in the quarter validates our view that driving clinical adoption builds both procedure revenue and market interest,' STXS president and CEO Michael P. Kaminski stated in the press release.
"The Company reported that the largest increase of capital orders was from North America where it has focused on clinical adoption. CEO Kaminski said that procedures in the United States are steadily increasing, resulting in higher utilization and stronger reference sites."
To read the entire report visit: http://www.microstockprofit.com/lp/STXS
See what investors are saying about STXS at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.